Prolonged tyrosine kinase activation of insulin receptor by pY27-caveolin-2

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 49-55

  Kwon, Hayeong ^a   Pak, Yunbae ^a  

^a PMBBRC   (South Korea)

Author keywords

Insulin receptor; IRS 1; pS727 STAT3; PTPs; pY27 caveolin 2; Rapamycin; SOCS 3

Indexed keywords

CAVEOLIN 2; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN TYROSINE KINASE; PS727 PROTEIN; PY27 CAVEOLIN 2; RAPAMYCIN; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; CAVEOLIN 2; CELL LINE; ENZYME ACTIVATION; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MICE; MUTATION; PHOSPHORYLATION; RATS; RECEPTOR, INSULIN; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TYROSINE;

EID: 72949111778     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.159     Document Type: Article

References (41)

1. Nystrom F.H., and Quon M.J. Insulin signalling: metabolic pathways and mechanisms for specificity. Cell. Signal. 11 (1999) 563-574
2. White M.F., and Kahn C.R. The insulin signaling system. J. Biol. Chem. 269 (1994) 1-4
3. Saltiel A.R., and Pessin J.E. Insulin signaling pathways in time and space. Trends Cell Biol. 12 (2002) 65-71
4. Bevan P. Insulin signaling. J. Cell Sci. 114 (2001) 1429-1430
5. Backer J.M., Kahn C.R., and White M.F. The dissociation and degradation of internalized insulin occur in the endosomes of rat hepatoma cells. J. Biol. Chem. 265 (1990) 14828-14835
6. Authier F., Rachubinski R.A., Posner B.I., and Bergeron J.J. Endosomal proteolysis of insulin by an acidic thiol metalloprotease unrelated to insulin degrading enzyme. J. Biol. Chem. 269 (1994) 3010-3016
7. Lai W.H., Cameron P.H., Wada I., Doherty II J.J., Kay D.G., Posner B.I., and Bergeron J.J. Ligand-mediated internalization, recycling, and downregulation of the epidermal growth factor receptor in vivo. J. Cell Biol. 109 (1989) 2741-2749
8. Goldstein B.J. Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. Receptor 3 (1993) 1-15
9. Wälchli S., Curchod M.L., Gobert R.P., Arkinstall S., and Hooft van Huijsduijnen R. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. J. Biol. Chem. 275 (2000) 9792-9796
10. Emanuelli B., Peraldi P., Filloux C., Sawka-Verhelle D., Hilton D., and Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 275 (2000) 15985-15991
11. Emanuelli B., Peraldi P., Filloux C., Chavey C., Freidinger K., Hilton D.J., Hotamisligil G.S., and Van Obberghen E. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J. Biol. Chem. 276 (2001) 47944-47949
12. Ueki K., Kondo T., and Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 24 (2004) 5434-5446
13. Auernhammer C.J., Bousquet C., and Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc. Natl. Acad. Sci. USA 96 (1999) 6964-6969
14. Kim J.H., Kim J.E., Liu H.Y., Cao W., and Chen J. Regulation of IL-6 induced hepatic insulin resistance by mTOR through the STAT3-SOCS3 pathway. J. Biol. Chem. 283 (2008) 708-715
15. Ueki K., Kondo T., Tseng Y.H., and Kahn C.R. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 101 (2004) 10422-10427
16. Razani B., Woodman S.E., and Lisanti M.P. Caveolae: from cell biology to animal physiology. Pharmacol. Rev. 54 (2002) 431-467
17. Liu P., Rudick M., and Anderson R.G. Multiple functions of caveolin-1. J. Biol. Chem. 277 (2002) 41295-41298
18. Jasmin J.F., Mercier I., Sotgia F., and Lisanti M.P. SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. Trends Endocrinol. Metab. 17 (2006) 150-158
19. Cohen A.W., Hnasko R., Schubert W., and Lisanti M.P. Role of caveolae and caveolins in health and disease. Physiol. Rev. 84 (2004) 1341-1379
20. Williams T.M., and Lisanti M.P. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am. J. Physiol. Cell Physiol. 288 (2005) C494-C506
21. Kim S., and Pak Y. Caveolin-2 regulation of the cell cycle in response to insulin in Hirc-B fibroblast cells. Biochem. Biophys. Res. Commun. 330 (2005) 88-96
22. Kwon H., Jeong K., and Pak Y. Identification of pY19-caveolin-2 as a positive regulator of insulin-stimulated actin cytoskeleton-dependent mitogenesis. J. Cell. Mol. Med. 13 (2009) 1549-1564
23. Kwon H., Jeong K., Hwang E.M., Park J.-Y., Hong S.-G., Choi W.-S., and Pak Y. Caveolin-2 regulation of STAT3 transcriptional activation in response to insulin. Biochim. Biophys. Acta 1793 (2009) 1325-1333
24. McClain D.A., Maegawa H., Lee J., Dull T.J., Ulrich A., and Olefsky J.M. A mutant insulin receptor with defective tyrosine kinase displays no biologic activity and does not undergo endocytosis. J. Biol. Chem. 262 (1987) 14663-14671
25. Jhun B.H., Haruta T., Meinkoth J.L., Leitner W., Draznin B., Saltiel A.R., Pang L., Sasaoka T., and Olefsky J.M. Signal transduction pathways leading to insulin-induced early gene induction. Biochemistry 34 (1995) 7996-8004
26. Pirola L., Johnston A.M., and Van Obberghen E. Modulation of insulin action. Diabetologia 47 (2004) 170-184
27. Zick Y. Uncoupling insulin signalling by serine/threonine phosphorylation: a molecular basis for insulin resistance. Biochem. Soc. Trans. 32 (2004) 812-816
28. Wang X.B., Lee H., Capozza F., Marmon S., Sotgia F., Brooks J.W., Campos-Gonzalez R., and Lisanti M.P. Tyrosine phosphorylation of caveolin-2 at residue 27: differences in the spatial and temporal behavior of phospho-Cav-2 (PY19 and pY27). Biochemistry 43 (2004) 13694-13706
29. Couet J., Sargiacomo M., and Lisanti M.P. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. J. Biol. Chem. 272 (1997) 30429-30438
30. Yamamoto M., Toya Y., Schwencke C., Lisanti M.P., Myers Jr. M.G., and Ishikawa Y. Caveolin is an activator of insulin receptor signaling. J. Biol. Chem. 273 (1998) 26962-26968
31. Yokogami K., Wakisaka S., Avruch J., and Reeves S.A. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. 10 (2000) 47-50
32. Fung M.M., Rohwer F., and McGuire K.L. IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells. Cell. Signal. 15 (2003) 625-636
33. Ozawa Y., Nakao K., Shimazaki T., Shimmura S., Kurihara T., Ishida S., Yoshimura A., Tsubota K., and Okano H. SOCS3 is required to temporally fine-tune photoreceptor cell differentiation. Dev. Biol. 303 (2007) 591-600
34. He A., Zhu L., Gupta N., Chang Y., and Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol. Endocrinol. 21 (2007) 2785-2794
35. Lopez I.P., Milagro F.I., Marti A., Moreno-Aliaga M.J., Martinez J.A., and De Miguel C. Gene expression changes in rat white adipose tissue after a high-fat diet determined by differential display. Biochem. Biophys. Res. Commun. 318 (2004) 234-239
36. Engelman J.A., Zhang X.L., and Lisanti M.P. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett. 448 (1999) 221-230
37. Oshimo Y., Kuraoka K., Nakayama H., Kitadai Y., Yoshida K., Chayama K., and Yasui W. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int. J. Cancer 112 (2004) 1003-1009
38. He B., You L., Xu Z., Mazieres J., Lee A.Y., and Jablons D.M. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer. Clin. Lung Cancer 5 (2004) 366-370
39. Scherer P.E., Lewis R.Y., Volonte D., Engelman J.A., Galbiati F., Couet J., Kohtz D.S., van Donselaar E., Peters P., and Lisanti M.P. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J. Biol. Chem. 272 (1997) 29337-29346
40. Racine C., Bélanger M., Hirabayashi H., Boucher M., Chakir J., and Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 255 (1999) 580-586
41. Fong A., Garcia E., Gwynn L., Lisanti M.P., Fazzari M.J., and Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol. 120 (2003) 93-100